These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 19838081)

  • 1. Involvement of glypican-3 in the recruitment of M2-polarized tumor-associated macrophages in hepatocellular carcinoma.
    Takai H; Ashihara M; Ishiguro T; Terashima H; Watanabe T; Kato A; Suzuki M
    Cancer Biol Ther; 2009 Dec; 8(24):2329-38. PubMed ID: 19838081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The expression profile of glypican-3 and its relation to macrophage population in human hepatocellular carcinoma.
    Takai H; Kato A; Kato C; Watanabe T; Matsubara K; Suzuki M; Kataoka H
    Liver Int; 2009 Aug; 29(7):1056-64. PubMed ID: 19141032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Significance of glypican-3 mRNA expression in hepatocellular carcinoma tissues and peripheral blood cells].
    Li BD; Zhao QC; Zhu YT; Zhang FQ; Dou KF
    Zhonghua Wai Ke Za Zhi; 2006 Apr; 44(7):458-62. PubMed ID: 16772080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of glypican-3 expression via RNA interference influences the growth and invasive ability of the MHCC97-H human hepatocellular carcinoma cell line.
    Ruan J; Liu F; Chen X; Zhao P; Su N; Xie G; Chen J; Zheng D; Luo R
    Int J Mol Med; 2011 Oct; 28(4):497-503. PubMed ID: 21617840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrence and poor prognosis following resection of small hepatitis B-related hepatocellular carcinoma lesions are associated with aberrant tumor expression profiles of glypican 3 and osteopontin.
    Yu MC; Lee YS; Lin SE; Wu HY; Chen TC; Lee WC; Chen MF; Tsai CN
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S455-63. PubMed ID: 21822558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long non-coding RNA cox-2 prevents immune evasion and metastasis of hepatocellular carcinoma by altering M1/M2 macrophage polarization.
    Ye Y; Xu Y; Lai Y; He W; Li Y; Wang R; Luo X; Chen R; Chen T
    J Cell Biochem; 2018 Mar; 119(3):2951-2963. PubMed ID: 29131381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ligustilide counteracts carcinogenesis and hepatocellular carcinoma cell-evoked macrophage M2 polarization by regulating yes-associated protein-mediated interleukin-6 secretion.
    Yang J; Xing Z
    Exp Biol Med (Maywood); 2021 Sep; 246(17):1928-1937. PubMed ID: 34053234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced nucleic ZHX2 involves in oncogenic activation of glypican 3 in human hepatocellular carcinoma.
    Luan F; Liu P; Ma H; Yue X; Liu J; Gao L; Liang X; Ma C
    Int J Biochem Cell Biol; 2014 Oct; 55():129-35. PubMed ID: 25195714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histopathological analyses of the antitumor activity of anti-glypican-3 antibody (GC33) in human liver cancer xenograft models: The contribution of macrophages.
    Takai H; Kato A; Kinoshita Y; Ishiguro T; Takai Y; Ohtani Y; Sugimoto M; Suzuki M
    Cancer Biol Ther; 2009 May; 8(10):930-8. PubMed ID: 19276671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The significance of glypican-3 expression profiling in the tumor cellular origin theoretical system for hepatocellular carcinoma progression.
    Xue R; Feng J; Meng Q; Lv F; Zhu Y; Yu H; Zhang S; Song C; Sun L; Yue Z; Feng S; Che R; Xiang Q; Jing X
    J Gastroenterol Hepatol; 2017 Aug; 32(8):1503-1511. PubMed ID: 28087980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glypican-3 promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells through ERK signaling pathway.
    Wu Y; Liu H; Weng H; Zhang X; Li P; Fan CL; Li B; Dong PL; Li L; Dooley S; Ding HG
    Int J Oncol; 2015 Mar; 46(3):1275-85. PubMed ID: 25572615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-148b-colony-stimulating factor-1 signaling-induced tumor-associated macrophage infiltration promotes hepatocellular carcinoma metastasis.
    Ke M; Zhang Z; Cong L; Zhao S; Li Y; Wang X; Lv Y; Zhu Y; Dong J
    Biomed Pharmacother; 2019 Dec; 120():109523. PubMed ID: 31655310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Glypican-3-Binding Peptide for in Vivo Hepatocellular Carcinoma Fluorescent Imaging.
    Zhu D; Qin Y; Wang J; Zhang L; Zou S; Zhu X; Zhu L
    Bioconjug Chem; 2016 Mar; 27(3):831-9. PubMed ID: 26850086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upregulation of Glypican-3 expression in hepatocellular carcinoma but downregulation in cholangiocarcinoma indicates its differential diagnosis value in primary liver cancers.
    Man XB; Tang L; Zhang BH; Li SJ; Qiu XH; Wu MC; Wang HY
    Liver Int; 2005 Oct; 25(5):962-6. PubMed ID: 16162153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SIRT4 silencing in tumor-associated macrophages promotes HCC development via PPARδ signalling-mediated alternative activation of macrophages.
    Li Z; Li H; Zhao ZB; Zhu W; Feng PP; Zhu XW; Gong JP
    J Exp Clin Cancer Res; 2019 Nov; 38(1):469. PubMed ID: 31744516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The glypican 3 hepatocellular carcinoma marker regulates human hepatic stellate cells via Hedgehog signaling.
    Magistri P; Leonard SY; Tang CM; Chan JC; Lee TE; Sicklick JK
    J Surg Res; 2014 Apr; 187(2):377-85. PubMed ID: 24439425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Transcription of
    Gou Y; Yang D; Tian T; Zhu X; Zhang R; Ren J; Tu D; Luo Y; Miao Y; Zhao H; Wang Y; Wei B
    Front Immunol; 2022; 13():725595. PubMed ID: 35371096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined functional genome survey of therapeutic targets for hepatocellular carcinoma.
    Satow R; Shitashige M; Kanai Y; Takeshita F; Ojima H; Jigami T; Honda K; Kosuge T; Ochiya T; Hirohashi S; Yamada T
    Clin Cancer Res; 2010 May; 16(9):2518-28. PubMed ID: 20388846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A functional screening identifies five microRNAs controlling glypican-3: role of miR-1271 down-regulation in hepatocellular carcinoma.
    Maurel M; Jalvy S; Ladeiro Y; Combe C; Vachet L; Sagliocco F; Bioulac-Sage P; Pitard V; Jacquemin-Sablon H; Zucman-Rossi J; Laloo B; Grosset CF
    Hepatology; 2013 Jan; 57(1):195-204. PubMed ID: 22865282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice.
    Dargel C; Bassani-Sternberg M; Hasreiter J; Zani F; Bockmann JH; Thiele F; Bohne F; Wisskirchen K; Wilde S; Sprinzl MF; Schendel DJ; Krackhardt AM; Uckert W; Wohlleber D; Schiemann M; Stemmer K; Heikenwälder M; Busch DH; Richter G; Mann M; Protzer U
    Gastroenterology; 2015 Oct; 149(4):1042-52. PubMed ID: 26052074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.